China Oncology ›› 2017, Vol. 27 ›› Issue (10): 829-832.doi: 10.19401/j.cnki.1007-3639.2017.10.011

Previous Articles     Next Articles

Advances in immunotherapy for metastatic renal cancer

CAO Dalong, YE Dingwei   

  1. Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Online:2017-10-30 Published:2017-12-05
  • Contact: YE Dingwei E-mail:

Abstract: Renal cancer is one of the most common genitourinary carcers. However, 25% patients present with locally invasive or metastatic renal cancer at the time of diagnosis, and one third of patients who received  esection of localized disease will have a recurrence or progression. Recently, immunotherapy for renal cancer has made significant progress. Especially, some immunotherapeutic agents (such as immune checkpoint inhibitor, tumor vaccine) have been proved to improve the prognosis of patients with metastatic renal cancer. In this review, the effects of immunotherapeutic agents in the treatment of renal cancer were summarized.

Key words: Metastatic renal cancer, Immunotherapy, Immune checkpoint inhibitor, Tumor vaccine